Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 7/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.39 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4343197 | 0.84 | DYRK1A (0.44) | MAPK1DYRK1AGSK3AGSK3BLRRK2 | |
| SCHEMBL4339193 | 0.81 | APOL1 (0.42) | MAPK1DYRK1AMAP2K4 | |
| SCHEMBL13635356 | 0.79 | TTK (0.50) | MAPK1GSK3AGSK3BMAP2K4MAP2K7 | |
| SCHEMBL2870208 | 0.78 | GSK3B (0.51) | MAPK1DYRK1AGSK3AGSK3BMAP2K4 | |
| SCHEMBL4331277 | 0.76 | MAPK1 (0.47) | MAPK1 | |
| SCHEMBL2864745 | 0.76 | MAP2K4 (0.58) | MAPK1GSK3AGSK3BMAP2K4MAP2K7 | |
| SCHEMBL2861793 | 0.76 | DYRK1A (0.53) | DYRK1AGSK3AGSK3BMAP2K4MAP2K7 | |
| SCHEMBL2866807 | 0.75 | DYRK1A (0.52) | DYRK1AGSK3AGSK3BMAP2K4MAP2K7 | |
| SCHEMBL4336457 | 0.74 | MAPK1 (0.50) | MAPK1MAP2K4MAP2K7 | |
| SCHEMBL2868590 | 0.74 | DYRK1A (0.50) | DYRK1AGSK3AGSK3BMAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAPK1 1/4885DYRK1A 1216/4885GSK3A 1159/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAPK1 1/4885DYRK1A 1216/4885GSK3A 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.